Clinical Trial

A 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex Generalized

Study acronym: EBULO
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 24, 2025 (before its estimated October 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to Assessing the Efficacy and Safety of Apremilast in Patients \> 6 years of age with EB simplex generalized . The main question it aims to answer are: describe efficacity of this treatment. Participants will take treatments and have to use bullets during the study period.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-07-18; most recent amendment 2025-02-21.
Status change: Not Yet Recruiting → Recruiting 2024-10-18
Trial Details
NCT Number NCT06509984
Lead Sponsor Centre Hospitalier Universitaire de Nice
Conditions Epidermolysis Bullosa Simplex, Genodermatosis
Enrollment 20 participants
Start Date 2024-08-06
Primary Completion 2025-10-01 (estimated)
Study Completion 2026-04-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-24